Sanofi Pasteur Inc.

Address: 1 Discovery Drive

Sponsor Overview

assignment

Specializations

pneumococcal conjugate vaccines

Research activity centers on pneumococcal immunization across infants, toddlers, children, and adolescents, with attention to immune responses against multiple serotypes and the comparative performance of 21-valent formulations.

serotype-specific immunogenicity
opsonophagocytic activity
safety and tolerability
catch-up vaccination

The portfolio includes evaluation of IgG antibody responses and functional antibody activity in pediatric age groups.

meningococcal vaccines

Clinical research includes meningococcal immunization in healthy children, toddlers, and infants, with focus on multivalent coverage for serogroups A, C, W-135, Y, and MenB reference strains.

pentavalent meningococcal vaccine
humoral immune response
pediatric vaccination schedules
serogroup coverage

Work in this area emphasizes immune responses measured after routine pediatric vaccination time points.

respiratory syncytial virus prevention

The sponsor funds research in virus diseases, especially respiratory syncytial virus prevention in infants and toddlers, with interest in protection against lower respiratory tract disease.

RSV vaccine
lower respiratory tract disease
pediatric viral infection
immune protection

These studies address both efficacy and safety in early childhood populations.

pediatric immunization across age groups

Across its vaccine programs, the clinical landscape spans healthy infants, preterm infants, toddlers, children, and adolescents, reflecting a strong focus on age-appropriate immunization strategies.

immune response assessment
age-specific vaccination
pediatric safety evaluation
comparative vaccine immunogenicity

Research sites are distributed internationally across multiple countries, supporting broad pediatric vaccine development.

Sponsored Trials

Trial Name	Country	Status
Evaluation of Immunogenicity and Safety of Pentavalent Meningococcal ABCYW Vaccine in Pediatric Populations Compared to Licensed Meningococcal Vaccines	Czechia Denmark Finland Germany Poland Spain	Not Recruiting
Phase 3 Randomized Study on Safety and Immunogenicity of 21-Valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers	Belgium Czechia Estonia Finland Germany Greece Italy Poland The Netherlands	Not Recruiting
Phase 3 Study on Safety and Immunogenicity of 21-Valent Pneumococcal Conjugate Vaccine in Pediatric and Adolescent Populations	Estonia Poland	Not Recruiting
Phase I/II Randomized Placebo‑Controlled Dose‑Finding Study of Intramuscular MRT1800 mRNA Vaccine (Combination Therapy) in Adults 18–45 Years with Moderate‑to‑Severe Acne	Germany Poland Spain	Not Yet Recruiting
Phase III Randomized Observer-Blind Placebo-Controlled Study of Live Attenuated RSV ΔNS2/Δ1313/I1314L Vaccine in Infants and Toddlers for RSV LRTD Prevention	Finland Germany Spain	Not Recruiting